United States

Analyst Research Report Snapshot


Q3 Revenue up 7.2%; EBITDA up 17%; Net Earnings up 34%




PI Financial Corp


30 Oct 2013





Companies referenced:


Available for Immediate Download

EARNINGS UPDATE October 29, 2013 CRH MEDICAL CORPORATION (T-CRH) $0.77 RATING: N/R TARGET: N/R (unchanged) (unchanged) Q3 Revenue up 7.2%; EBITDA up 17%; Net Earnings up 34% VALUATION/RECOMMENDATION: The shares of CRH Medical Corporation are up over 190% year-to-date. CRH is a NON-RATED company and we do not provide a target price. CRH currently trades at a 12x EV/EBITDA multiple based on our 2014 forecast. CRH is a micro-cap stock with limited share liquidity and limited cash reserves. As such, we assess an investment in CRH Medical Corporation as a SPECULATIVE risk rating. Company Statistics Risk: SPECULATIVE 52 week High / Low: $0.79 / $0.25 Shares Outstanding: 48.7M Shares Outstanding: 53.1M Market Capitalization: $40.9M Market Float: 44.8M Quoted Market Value: $34.5M 30 Day Av. Daily Volume: 89,482 Cash: $6.2M Net Debt/Capital: 0.0% CEO: Edward Wright Chairman: Anthony Holler Shareholders: Dir. & Officers 8.0% Financial Summary (FYE Dec. 31) (US$000's except EPS) 2011 2012 2013e 2014e Revenue 5,533 6,849 7,505 8,630 Gross profit 2,924 3,079 3,443 4,046 Gross profit margin 53% 45% 46% 47% EBITDA 1,515 1,862 2,012 2,456 EBITDA % 27.4% 27% 27% 28% Net earn. cont. ops 1,156 1,332 1,687 2,026 EPS cont. ops. $0.02 $0.03 $0.03 $0.04 EV/EBITDA 23x 18x 15x 12x Financials in US$; Stock related metrics assumes 1US$=1C$ Corporate Information CRH Medical Corporation (T-CRH) based in Vancouver, is a direct-to-physician distributor of a proprietary product to treat hemorrhoids in the US. CRH markets a treatment solution to gastroenterologists and general surgeons. We expect CRH to add complementary products/services to grow long-term revenue.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.